Drugs / Typhax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03926455 | Mar 2016 → Feb 2017 | typhoid fever | Matrivax Research and Development Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03926455 ↗ |
| Modality | Vaccine | “Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.” PMID 31905228 ↗ Jan 2020 |